Evolution of periodontal ligament stem cells and their laden scaffolds as game changers in oral and maxillofacial reconstruction
Tissue and Cell · vol. 104 (Pt 2) · 103895-103895
المخرجات
Articles, reviews, conference papers and book chapters, indexed by DOI and linked to University researchers.
49 output Results for «Stem cell»
Tissue and Cell · vol. 104 (Pt 2) · 103895-103895
Stem Cell Research & Therapy · vol. 17 (1)
BACKGROUND: Severe COVID-19 is marked by a dysregulated inflammatory response, known as a cytokine storm, resulting in acute respiratory distress syndrome (ARDS) and multiple organ failure. Mesenchymal stem cell-derived exosomes (MSC-Exos) have demonstrated potential as immunomodulatory agents. This work investigates the possibility of MSC-Exos to mitigate excessive inflammation in COVID-19 by targeting the mitogen-activated protein kinase (MAPK) signalling pathway. METHODOLOGY: We integrated molecular docking analysis between TGF-β and Annexin A1 as exosomal proteins and key component proteins of the MAPK pathway (p38, ERK1/2, JNK1). The in-silico results were then validated in vivo using a Syrian hamster model of SARS-CoV-2 infection. Quantitative PCR (qPCR), western blotting, and histological examination were employed to evaluate the effects of MSC-Exos therapy on MAPK pathway activation, cytokine production, and lung tissue pathology. RESULTS: The in-silico study revealed extensive hydrogen bonding and hydrophobic interactions at the protein-protein interfaces between exosomal proteins and MAPK components. These interactions suggest that exosomal proteins may modulate MAPK signaling pathways. In vivo, MSC-Exos administration led to marked downregulation of pivotal genes in the MAPK signaling pathway (MEKK1, MEKK2, MEKK3), diminished phosphorylation of JNK1, p38, and ERK1/2, and lowered production of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). Histopathological examination demonstrated ameliorated lung tissue structure, characterized by diminished alveolar wall thickness and decreased immune cell infiltration. CONCLUSION: MSC-Exos elicit immunomodulatory effects in SARS-CoV-2-Infected hamsters, partially by directly targeting and blocking the MAPK signaling pathway. These findings offer a compelling justification for the clinical assessment of MSC-Exos as a therapeutic approach to alleviate the cytokine storm and enhance outcomes in severe COVID-19 by targeting the ACE2-Independent pathway.
Biomedicine & Pharmacotherapy · vol. 201 · 119684-119684
Biomedicine & Pharmacotherapy · vol. 201 · 119641-119641
Applied Biochemistry and Biotechnology · vol. 198 (7) · 5250-5268
Clinical Cosmetic and Investigational Dermatology · vol. Volume 18 · 2215-2227
Mesenchymal stem cell (MSC)-derived exosomes are recognized a promising cell-free therapy for alopecia. These nano-vesicles facilitate intercellular communication and contain a variety of bioactive molecules that can potentially stimulate hair follicle regeneration. However, the safety and efficacy of exosome therapy for alopecia remains to be determined. This systematic analysis aimed to determine the clinical safety and effectiveness of exosome therapy for hair growth, particularly androgenetic alopecia (AGA) and other forms of hair loss. Systematic searches were conducted on PubMed, Scopus, and Embase databases to find clinical studies published from inception until 10th May 2025 that explored exosome-based interventions for hair loss. Eleven studies included: two RCTs, three retrospective studies, three prospective single-arm studies, one case series, and two case reports. Extracted data included method of preparation, outcomes of hair regrowth (density, thickness, patient satisfaction), and side effects. Quality of evidence was assessed using the Oxford Centre for Evidence-Based Medicine (OCEBM) levels and risk of bias tools (RoB 2 and ROBINS-I). All the studies included demonstrated improvements in at least one hair parameter, with MSC-derived exosomes from adipose tissue, placenta, hair follicles, bone marrow, foreskin, and umbilical cord having substantial increases in hair density (9.5 to 35 hairs/cm²) and hair thickness (up to 13.01 µm). Patient satisfaction was generally high (3-10 point scales), and no serious adverse events were noted. The greatest level of evidence came from RCTs with adipose- and plant extract-derived exosome formulation. However, heterogeneity in design and outcome limited direct comparisons. Exosome therapy, particularly with MSC-derived sources, appears to be a new and safe treatment modality for hair restoration in AGA and other alopecias. The current evidence is, however, limited by heterogeneity in studies, small sample sizes, and varying follow-up durations. More well-standardized, high-quality RCTs are required to confirm these findings and establish standardized treatment protocols.
Frontiers in Bioengineering and Biotechnology · vol. 13 · 1571066-1571066
Urine-based therapy, an ancient practice, has been utilized across numerous civilizations to address a wide range of ailments. Urine was considered a priceless resource in numerous traditional therapeutic applications due to its reported medicinal capabilities. While the utilization of urine treatment is contentious and lacks significant support from modern healthcare, the discovery of urine-derived stem cells (UDSCs) has introduced a promising avenue for cell-based therapy. UDSCs offer a noninvasive and easily repeatable collection method, making them a practical and viable option for therapeutic applications. Research has shown that UDSCs contribute to organ preservation by promoting revascularization and decreasing inflammatory reactions in many diseases and conditions. This review will outline the contemporary status of UDSCs research and explore their potential applications in both fundamental science and medical practice.
BioMedical Engineering OnLine · vol. 24 (1) · 31-31
BACKGROUND: Primary osteoblasts are essential for bone formation and regeneration, making them pivotal in dental applications, including periodontal regeneration, ridge augmentation, and implant osseointegration. Sourced from various tissues like alveolar bone, calvarial bone, mandibular and maxillary bones, long bones, and bone marrow-derived stem cells (BMSCs), each type of osteoblast presents unique advantages and limitations related to yield, accessibility, and clinical relevance. Given these variables, selecting an appropriate source is crucial for experimental consistency and translational application in dentistry. METHODS: This review synthesizes data from in vitro, animal, and clinical studies to provide a comprehensive overview of osteoblast sourcing, isolation, and characterization in dental research. Sources were reviewed based on yield, anatomical relevance, and accessibility, while isolation methods were compared to assess their impact on cell behavior and phenotype retention. The review evaluates methods such as enzymatic digestion, explant culture, and differentiation of BMSCs, alongside characterization techniques like morphological analysis, gene expression profiling, and mineralization assays. RESULTS: The analysis shows that alveolar bone-derived osteoblasts offer high clinical relevance due to their anatomical similarity to oral structures but are limited by low yield and invasive collection. Calvarial and long bone osteoblasts provide higher yields, making them useful for material testing, though they lack biomechanical compatibility with oral environments. BMSCs offer a renewable source with significant regenerative potential but require precise differentiation protocols. In vitro studies contribute mechanistic insights, while animal models bridge the gap to clinical application, despite challenges in standardization and interspecies variability. CONCLUSION: This review highlights the importance of selecting appropriate osteoblast sources and methods for dental research to optimize outcomes in periodontal and implant-related therapies. The variability across study designs and experimental outcomes underscores the need for standardized protocols and targeted systematic reviews within specific research settings. These findings offer a framework for future osteoblast-based research and guide the effective translation of osteoblast therapies into clinical dental practice.
Frontiers in Pharmacology · vol. 16 · 1622018-1622018
Introduction: Repetitive traumatic brain injury (RTBI) represents a cumulative neurological insult associated with progressive neurodegeneration and limited therapeutic options. In this study, we uniquely evaluate the neuroprotective potential of mesenchymal stem cell (MSC)-derived exosomes in a rat model of RTBI, an area scarcely explored. Methods: RTBI was induced via a controlled mechanical impact to the skull once every day for 5 days. MSC-derived exosomes were administered 24 h after the final insult in two paradigms: a single dose (MSC-Ex1) with 2 weeks of follow-up, and a dual dose (MSC-Ex2) given 1 week apart, with sacrifice 1 week later. Rats were assigned to four groups: control, RTBI, RTBI + MSC-Ex1, and RTBI + MSC-Ex2. Results: MSC-derived exosome regimens comparably restored cognitive performance in the Novel Object Recognition and Y-maze tests. While both treatment paradigms preserved cortical histoarchitecture, the double-dose regimen led to a more pronounced restoration compared to the moderate tissue recovery observed in the single-dose group. Crucially, this work identifies parthanatos inhibition as a novel mechanistic axis for MSC-derived exosomes-mediated neuroprotection. MSC-derived exosomes attenuated excitotoxicity and oxidative stress, quelling the parthanatos cascade by suppressing PARP1, PAR polymers, nuclear AIF and MIF, as well as calpain, key executors of this caspase-independent cell death pathway. Additionally, MSC-derived exosomes normalized cyclophilin B and Hsp70 levels, suggesting their compensatory role in modulating the endogenous stress response. Conclusion: Overall, these findings demonstrate that MSC-derived exosomes counteract RTBI-induced neurodegeneration through multifaceted mechanisms, with parthanatos suppression at the core. Importantly, the dual-dosing regimen conferred no significant benefit over the single dose, highlighting the therapeutic promise of early intervention. This study positions MSC-derived exosomes as a novel, cell-free therapy capable of intercepting RTBI-induced neuropathology by targeting an under recognized form of programmed cell death.
Stem Cell Research & Therapy · vol. 16 (1) · 244-244
BACKGROUND: The JAK/STAT signaling pathway plays a crucial role in the release of interferons (IFNs) and the proinflammatory response during SARS-CoV-2 infection, contributing to the cytokine storm characteristic of severe COVID-19 cases. STAT3, a key protein in this pathway, has been implicated in promoting inflammation, making its inhibition a potential therapeutic strategy to mitigate disease severity. Mesenchymal Stem Cell-derived Extracellular Vesicles (MSC-EVs), enriched with immunomodulatory and antiviral miRNAs, offer a promising therapeutic approach by modulating gene expression and regulating inflammatory responses. This study investigates the ability of Lyophilized MSC-EVs to inhibit the JAK/STAT pathway, highlighting their potential application in COVID-19 management. METHODS: Male Syrian hamsters were used as an experimental model, housed under controlled laboratory conditions. SARS-CoV-2 (hCoV-19/Egypt/NRC-03/2020) was propagated in Vero E6 cells, and viral titers were determined using plaque assays. Hamsters were intranasally challenged with the virus and treated intraperitoneally with 0.5 mL of lyophilized human Wharton's jelly-derived MSC-extracellular vesicles (MSC-EVs). Histopathological evaluations were performed on lung tissues using H&E, Masson's trichrome, and immunohistochemical staining. Morphometric analyses were conducted to assess lung injury and fibrosis. Western blotting was employed to evaluate protein expression. All procedures adhered to ethical and biosafety guidelines. RESULTS: The administration of MSC-EVs significantly upregulated the expression levels of miRNA-146a, miRNA-124, miRNA-155, miRNA-29b, miRNA-7, miRNA-145 and miRNA-18a compared to their levels in the COVID-19 group, suggesting a targeted release of miRNA-cargo from the MSC-EVs into the lung tissue of the animals. MSC-EVs impaired the activation of the STAT3/STAT1 signaling pathway and reduced the cytokine storm and coagulopathy associated with COVID-19. CONCLUSIONS: These findings suggest that MSC-EVs have the potential to effectively mitigate the pathogenesis of COVID-19 by targeting the JAK/STAT signaling pathway. Further research is needed to fully understand the mechanisms underlying the therapeutic effects of MSC-EVs and their clinical application in combating the COVID-19 pandemic.
European Journal of Pharmacology · vol. 1007 · 178209-178209
Brain Disorders · vol. 18 · 100235-100235
• The pathogenesis of the disease multiple sclerosis (MS) is not well understood, but there are several existing theories. • MS is a demyelinating disease affecting the neurons of the central nervous system due to an immune-mediated process and leading to different neurological manifestations. • Its etiology is due to a network of interactions between genetic, immune, and environmental factors. • This comprehensive review paper offers recent insight through MS’s clinical manifestations, epidemiology, pathogenesis, and therapies, shedding light on some futuristic treatments for this disease. Multiple sclerosis (MS) is a chronic, immune-mediated neurological disorder that continues to challenge both researchers and clinicians. While advances in understanding its pathophysiology have led to improved disease-modifying therapies, these treatments primarily focus on immunosuppression and relapse prevention, leaving progressive forms of MS with limited options. Neurodegeneration, myelin loss, and long-term disability remain major hurdles, underscoring the urgent need for therapies that go beyond symptom management to actively repair damage and alter disease progression. With emerging breakthroughs in regenerative medicine, including stem cell-based therapies and novel immune-targeting treatments, we are entering a new era of MS research that prioritizes neuroprotection and repair. This review explores the latest insights into MS classification, pathogenesis, and treatment approaches, with a particular focus on cutting-edge therapies that hold the potential to shift MS care from disease suppression to long-term recovery. By bridging research and clinical application, this study aims to highlight the most promising avenues for future innovation and improved patient outcomes.
Journal of Advanced Trends in Medical Research · vol. 2 (4) · 671-681
Hair loss, or alopecia, encompasses a diverse range of conditions including both cicatricial (scarring) and non-cicatricial (non-scarring) forms, with significant implications for patients’ physical appearance, psychological well-being and overall quality of life. The limitations of traditional therapies such as topical agents, oral medications and hair transplantation have led to increasing interest in regenerative approaches. Amongst these, platelet-rich plasma (PRP) and exosome-based therapies have emerged as promising biologic interventions. PRP, derived from autologous blood, contains a high concentration of platelets rich in growth factors that support hair follicle regeneration, angiogenesis and cellular proliferation. Evidence suggests its potential benefits in various types of hair loss particularly androgenetic alopecia, alopecia areata and telogen effluvium, although standardised protocols, optimal dosing and long-term outcomes remain uncertain. Exosomes are small extracellular vesicles secreted by stem cells that offer a novel cell-free alternative capable of delivering complex molecular signals to modulate inflammation, stimulate follicular stem cells, and promote dermal remodeling. Early findings indicate possible applications across a range of alopecias including chemotherapy-induced hair loss, autoimmune related alopecia and structural hair shaft disorders such as trichorrhexis nodosa and monilethrix. This narrative review provides an updated overview of PRP and exosome-based therapies, outlining their mechanisms of action, clinical applications and current limitations. While both modalities show therapeutic promise, their biologic variability, lack of regulatory standardisation and need for comparative trials highlight critical gaps in evidence. Further research is warranted to establish reproducible treatment protocols and determine long-term efficacy and safety for clinical use.
Research Square
Abstract Endocrinologists and nephrologists continually seek new therapeutic approaches for diabetic nephropathy (DN). Lately, mesenchymal stem cells (MSCs)-derived exosomes (MSCs-EXs) have been applied as natural carriers for targeted drug delivery. Thus, we aim to estimate the therapeutic potentialities of MSCs-EXs loaded with ordinary selenium (Se) or its nanoform (NSe) as a promising cell-free therapy in diabetic nephropathy (DN). Eighty rats were randomly split into 8 groups; control, EXs, EXs + Se, EXs + NSe, diabetic (D), D + EXs, D + EXs + Se, and D + EXs + NSe groups. After 4 weeks, our results indicated renal hypolipidemic and renal ameliorating effects of unloaded or loaded EXs with Se or NSe, evidenced by the declined serum levels of urea, uric acid, and creatinine, compared to diabetic-untreated rats. Such observations might be a reflection of the observed antioxidant activity of both EXs alone or in the combined form with either Se or NSe, evidenced by decreased renal MDA, NO, H2O2 levels coupled with increased GSH, SOD, CAT, and GPX, besides their anti-inflammatory and antiapoptotic effects, indicated by the decreased renal levels of IL-6, TGF-β, TNF-α, BAX, caspase-3, and P53, with Bcl-2 upregulation. Consequently, the kidney architecture in the three diabetic-treated groups was greatly improved. Likely, the EXs-loaded NSe treatment protocol highlighted the DN improvement superiority most significantly compared to the other protocols.
Biomedicine & Pharmacotherapy · vol. 187 · 118042-118042